Generic Name and Formulations:
Rosiglitazone (as maleate), glimepiride; 4mg/1mg, 4mg/2mg, 4mg/4mg, 8mg/2mg, 8mg/4mg; tabs.
Various generic manufacturers
Indications for Rosiglitazone/Glimepiride:
Adjunct to diet and exercise for type 2 diabetes when dual therapy is appropriate.
≥18yrs: Take once daily with first meal of the day. Drug-naive: 4mg/1mg. Previously on thiazolidinedione monotherapy: initially 4mg/1mg or 4mg/2mg; if inadequate response after 1–2 weeks, may increase glimepiride component in ≤2mg increments at 1–2 week intervals. Previously on sulfonylurea monotherapy: initially 4mg/1mg or 4mg/2mg; if inadequate response, may increase rosiglitazone component after 8–12 weeks. Previously on rosiglitazone and glimepiride: switch on a mg/mg basis. Max 8mg rosiglitazone/4mg glimepiride per day. Elderly, debilitated, malnourished, renal, hepatic or adrenal insufficiency: initially 4mg/1mg once daily; titrate carefully to avoid hypoglycemia.
<18yrs: not established.
NYHA Class III or IV heart failure. Sulfonamide allergy.
Not for treating type 1 diabetes or diabetic ketoacidosis. Symptomatic HF or acute coronary syndromes: not recommended; discontinue if occurs. CHF: NYHA Class I or II: increased risk of cardiovascular events (monitor). Edema. May increase plasma volume (monitor for heart failure); discontinue if cardiac status deteriorates. Monitor for weight gain/fluid retention. Risk of cardiovascular mortality. Hepatic disease. Do not start therapy in active liver disease or if ALT >2.5xULN. Monitor transaminases at baseline, then periodically. If ALT is mildly elevated (≤2.5xULN), follow-up and monitor closely; discontinue if ALT >3xULN or jaundice occurs. Not for use in patients with history of troglitazone-associated jaundice. Risk of fractures (esp. women). G6PD deficiency. Stress, uncompensated strenuous exercise, deficient caloric intake, or alcohol intoxication: increased risk of hypoglycemia. Resumption of premenopausal ovulation in anovulatory patients may occur (may result in unintended pregnancy). Reevaluate if menstrual dysfunction occurs. Elderly. Labor & delivery. Pregnancy (Cat.C) (consider using insulin instead), nursing mothers: not recommended.
Thiazolidinedione + sulfonylurea.
Concomitant insulin or nitrates: not recommended. Potentiated by CYP2C8 inhibitors (eg, gemfibrozil). Antagonized by CYP2C8 inducers (eg, rifampin). May be potentiated by alcohol, NSAIDs, highly protein bound drugs, oral miconazole, salicylates, sulfonamides, chloramphenicol, warfarin, probenecid, MAOIs, β-blockers. May be antagonized by diuretics, corticosteroids, phenothiazines, thyroid products, phenytoin, niacin, sympathomimetics, isoniazid, estrogens, oral contraceptives. May be affected by CYP2C9 substrates (eg, rifampin, fluconazole). Separate colesevelam dosing by ≥4 hours. Monitor for 1–2 weeks if transferring from long-acting sulfonylureas.
Headache, hypoglycemia, nasopharyngitis, upper respiratory tract infection, injury, edema, weight gain, anemia, macular edema (possible), hypersensitivity reactions (eg, angioedema, Stevens-Johnson syndrome); discontinue if occurs. See full labeling re: risk of myocardial ischemic events.
Formerly known under the brand name Avandaryl.
Neurology Advisor Articles
- Rasagiline Plus Riluzole is Safe, May Improve Survival in ALS
- Treatment of New-Onset Epilepsy: AAN, AES Update Practice Guidelines
- Gender Differences in the Epidemiology of Migraine
- Changes in Glucose Regulation in Parkinson Disease
- Apomorphine Infusions Improves Off Time Associated With Parkinson Disease
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- Locally Asymptomatic Ischemic Stroke May Present as Migraine Aura
- Associations Identified Between Stroke Severity, Recovery of Visuospatial Neglect
- Action Tremor May Have Central Origin in Motor Neuron Disease
- Characteristics Affecting Health-Related Quality of Life in RRMS, Progressive MS
- Neurodevelopmental Anomalies, Birth Defects Linked to Zika ID'd